Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Poloxamer 188 BP EP USP Pharma Grade earns strong recognition across the pharmaceutical and chemical sectors as a block copolymer surfactant with qualities that make it useful for many industrial, medical, and research needs. Its molecular structure stands out: Poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene)—a non-ionic triblock arrangement—provides significant solubilizing properties. Manufacturers often call this material by several names, including Pluronic F68, which points to its global application and demand. The pharmaceutical grade meets three major compendium standards—British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP)—standing for strict quality and purity, which reduces many safety-related questions.
Poloxamer 188 comes with a formula of C62H126O26, and a typical molecular mass near 8700 g/mol. Shaped by its amphiphilic nature, it balances both hydrophilic and lipophilic elements. That unique balance gives it a reputation for performing reliably as an emulsifier, surfactant, solubilizer, and stabilizer. Normally, pure Poloxamer 188 appears as white or off-white solid flakes, powder, or pearls. It melts around 52°C to 57°C, transforms into a clear liquid at higher temperatures, and dissolves smoothly in water and alcohols. In my experience, it handles like a waxy granulized solid—easy to scoop and weigh. Density ranges between 1.06 g/cm³ and 1.09 g/cm³ for solid form, and it keeps that density steady across most pharmaceutical solutions. In the lab, I found solutions of Poloxamer 188 remain stable and clear, with no clumping or sedimentation, proving reliable even in high-concentration batches, which cuts down on waste and repeat processing.
Poloxamer 188’s core value sits in its surfactant properties, reducing surface tension between different phases, especially oil and water. In pharmaceuticals, that means drug solutions and suspensions benefit from improved solubility and better patient outcomes. As a solubilizer, Poloxamer 188 handles active pharmaceutical ingredients (APIs) that don’t otherwise dissolve in water, such as certain painkillers and antibiotics, leading to higher absorption. I’ve watched teams use it in parenteral products, like injections and infusions, for its stabilizing action and its safety track record. Its ability to form micelles means new drugs or nutrients can travel safely inside its hydrophobic core and remain stable until use. Hospitals trust it for blood substitutes and some dialysis fluids thanks to its high safety margins and biocompatibility, which studies confirm repeatedly.
Industry standards demand a high bar for purity, heavy metal content, microbial limits, loss on drying, and pH range. Specifications by USP, BP, and EP guide every batch. Typically, water content remains below 2%, pH in 5% aqueous solution stays between 6.0 and 7.4, and heavy metals table far beneath regulated thresholds. HS Code 3402.13.00 sits most commonly for trade, recognized for surface-active agents. Those details mean customs clearance runs smoother, with importers balancing safety and documentation headaches. For anyone qualifying drug raw materials, these are non-negotiable. I have handled supplier audits to ensure Poloxamer 188 complied with regulatory filings, noting the ease at which traceability and batch-to-batch consistency passed scrutiny—essential for global distribution.
Suppliers roll out Poloxamer 188 in flakes, fine powder, small pearls, or sometimes liquid concentrate for industrial dosing systems. Each form brings practical considerations. Flakes and powder pour easily, mix rapidly in vessels, and rarely cake in bulk containers. Pearls avoid dust, ideal where air filtration matters. Liquid and crystal options help high-speed automated processes skip manual scooping altogether. Flake and powder show a slight crystalline shine, confirming purity under lamp light. Handling each style, I found bulk powder moves best for compounding smaller pharmaceutical batches, while flakes suit large-scale dissolutions where dust control matters. High flow properties and consistent particle size speak to manufacturing ease and reduce handling risks or inconsistencies.
Poloxamer 188 ranks low in acute and chronic toxicity, which lifts it above harsher surfactants. Regulatory agencies classify it as non-carcinogenic and low in skin or eye irritation risks. Proper handling still belongs in every protocol—laboratory coats, gloves, eye protection. It might provoke mild irritation with repeated contact or inhalation in fume-heavy settings, but incidents stay rare. Its breakdown in water leaves behind minimal ecological risk compared to typical surfactants. Disposal often falls under standard non-hazardous chemical rules, bypassing extra hazardous waste logistics. I’ve managed chemical inventories that satisfied environmental safety inspections, and Poloxamer 188 never triggered red flags, which keeps audits fast and stress down for facilities.
Consistent supply of Poloxamer 188 depends on reliable sourcing of high-purity polyethylene oxide and polypropylene oxide, its raw input chemicals. As demands for solubilizers and excipients rise worldwide, competitive pricing and stable contracts prove crucial. Major manufacturers in the US, Europe, China, and India set the pace on purity and documentation. Supply chain disruptions—like container shortages or shifts in raw material costs—do affect batch prices. I have worked through shortages where sourcing from secondary regions kept manufacturing lines running, proving the need for multiple qualified suppliers and real-time inventory monitoring. Pharmaceutical companies guard their supply chains close to prevent material swap-outs that could stall production or violate regulatory declarations.
Every day, chemists, pharmacists, and plant operators trust that Poloxamer 188’s batch-to-batch uniformity prevents mistakes, recalling only rare incidents of off-grade lots. This reliability allows innovation: extended-release drugs, nano-encapsulated APIs, gene therapy vehicles, and more. Blending with solvents, acids, or bases rarely throws off its structure or performance. Long-term storage stays trouble-free if kept away from moisture, with shelf lives that often outlast competing surfactants. My experience storing raw powder for two years at room temperature showed no caking, no loss in clarity or solubility, and zero contamination detected on retest.
Rising environmental and regulatory pressures in pharmaceuticals mean excipient safety and traceability grow in importance. Poloxamer 188’s long record as a non-harmful substance helps maintain that balance. Greater use of digital monitoring during transport—like temperature sensors—will only increase confidence in imported materials. For buyers and handlers, keeping robust CoA (Certificate of Analysis) archives, supplier audit records, and regular on-site testing proves wise. As drugs become more complex, demand for better excipients remains. Exploring ways to increase batch size, reduce microplastic residue, and streamline recycling will help ensure Poloxamer 188 keeps its place as the go-to material for stable, safe, and high-performing formulations in the modern pharma landscape.
Chengguan District, Lanzhou, Gansu, China
